Sara M. Tolaney, MD, MPH

Articles

A Pooled Analysis of Trastuzumab Deruxtecan in Patients With HER2- Positive Metastatic Breast Cancer With Brain Metastases (BMs) from DESTINY-Breast01, -02, and -03

April 2nd 2024

Sara Tolaney, MD, MPH, presents an exploratory pooled analysis of efficacy and safety data of trastuzumab deruxtecan vs comparator in patients with HER2-positive metastatic breast cancer and brain metastases from DESTINY-Breast01, -02, and -03.

Dr Tolaney on the Real-World Efficacy of T-DXd in HER2+ or HER2-Low Breast Cancer

December 15th 2023

Sara M. Tolaney, MD, MPH, discusses the real-world efficacy of fam-trastuzumab deruxtecan in patients with HER2-positive or HER2-low metastatic breast cancer, including patients who experienced changes in HER2 status during the treatment course.

Dr Tolaney on Sequencing Available ADCs in Breast Cancer

December 8th 2023

Sara M. Tolaney, MD, MPH, discusses the current utilization of antibody-drug conjugates in patients with hormone receptor-positive, HER2-negative breast cancer, highlighting the question of sequencing among available agents.

Dr Tolaney on Final OS Data From the TROPiCS-02 Trial in HR+/HER2- Breast Cancer

June 7th 2023

Sara M. Tolaney, MD, MPH, discusses key data from a final overall survival analysis of the phase 3 TROPiCS-02 trial in hormone receptor–positive, HER2-negative breast cancer.

Closing Remarks on Treating Patients with HR+ Breast Cancer

February 13th 2023

Massimo Cristofanilli, MD, and Sara Tolaney, MD, MPH, offer closing remarks on the HR+ breast cancer treatment landscape, offer advice for community oncologists, and look to the future.

Treatment after Progression on CDK4/6 Inhibitors

February 6th 2023

A detailed look at treatment options for patients with metastatic HR+ breast cancer who have progressed on CDK4/6 inhibitors.

The Role of Surgery in Breast Cancer

February 6th 2023

Experts in oncology consider when surgery is appropriate for patients with breast cancer.

Overview of Treatment Options for Patients with Breast Cancer

January 30th 2023

Breast cancer experts provide a comprehensive overview of treatment options and clinical trials in breast cancer.

Patient Profile 2: A 62-Year-Old Woman with Metastatic HR+ Breast Cancer

January 30th 2023

Massimo Cristofanilli, MD, and Sara Tolaney, MD, MPH, analyze a patient case of a 62-year-old woman with metastatic HR+ breast cancer.

Clinical Insights on the Use of Adjuvant Therapy Plus Abemaciclib in HR+ Breast Cancer

January 23rd 2023

Detailed clinical insights on the use of adjuvant therapy plus abemaciclib in patients with high-risk, early stage HR+ breast cancer.

Abemaciclib Plus Adjuvant Endocrine Therapy in Breast Cancer

January 23rd 2023

Using the monarchE trial as a benchmark, experts in oncology discuss the use of abemaciclib with adjuvant endocrine therapy in patients with high-risk, early stage HR+ breast cancer.

Patient Profile 1: A 56-Year-Old Woman with Early HR+ Breast Cancer

January 16th 2023

Expert oncologists offer their initial impressions of a profile of a 56-year-old woman with early stage, HR+ breast cancer.

HR+ Breast Cancer: Incidence, Prognosis, and Risk Stratification

January 16th 2023

Sara Tolaney, MD, MPH, and Massimo Cristofanilli, MD, discuss factors that affect risk stratification of patients with HR+, HER2- breast cancer.

Updated Results of APHINITY at 8.4 Years Median Follow Up

November 17th 2022

Dr Sara M Tolaney reviews data from the APHINITY trial regarding the pertuzumab plus trastuzumab and chemotherapy treatment regimen for patients with HER2+ breast cancer.

Ongoing Clinical Trials With ADC Therapy in HR+ Metastatic Breast Cancer

November 1st 2022

Breast medical oncologists close out the program on HR+ metastatic breast cancer by highlighting ongoing clinical trials with antibody-drug conjugate therapy.

HR+ Metastatic Breast Cancer: What is the Role of Antibody-Drug Conjugates?

October 25th 2022

Centering discussion on antibody-drug conjugates in HR+ metastatic breast cancer, panelists consider the selection and use of these agents in practice.

HER2-Low Metastatic Breast Cancer and Use of Trastuzumab Deruxtecan

October 25th 2022

Centering their discussion on the HER2 low setting of HR+ metastatic breast cancer, medical oncologists review data behind trastuzumab deruxtecan therapy.

Treatment for HR+ Metastatic Breast Cancer After Progression on CDK4/6 Inhibitors

October 18th 2022

Shared insight on appropriate treatment options for patients with HR+ metastatic breast cancer following progression on CDK4/6 inhibitors.

HR+ Metastatic Breast Cancer: Continuing CDK4/6 Inhibition Beyond Progression

October 18th 2022

Expert panelists consider when it is appropriate to continue the use of CDK4/6 inhibitors beyond progression in HR+ metastatic breast cancer.

Interpreting Data With CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer

October 11th 2022

In the context of recent clinical trials, experts share their perspective on the selection and use of CKD4/6 inhibitor therapy in patients with HR+ metastatic breast cancer.